HSF1 Pathway Inhibitor Clinical Candidate (CCT361814/NXP800) Developed from a Phenotypic Screen as a Potential Treatment for Refractory Ovarian Cancer and Other Malignancies-Reference-Cited by-同舟云学术

HSF1 Pathway Inhibitor Clinical Candidate (CCT361814/NXP800) Developed from a Phenotypic Screen as a Potential Treatment for Refractory Ovarian Cancer and Other Malignancies

Published:2023-04-05 Issue:8 Volume:66 Page:5907-5936
ISSN:0022-2623
Container-title:Journal of Medicinal Chemistry
language:en
Short-container-title:J. Med. Chem.

Author:

Pasqua A. Elisa¹^ORCID,Sharp Swee Y.¹,Chessum Nicola E. A.¹^ORCID,Hayes Angela¹,Pellegrino Loredana¹,Tucker Michael J.¹,Miah Asadh¹,Wilding Birgit¹,Evans Lindsay E.¹,Rye Carl S.¹,Mok N. Yi¹^ORCID,Liu Manjuan¹,Henley Alan T.¹,Gowan Sharon¹,De Billy Emmanuel¹,te Poele Robert¹^ORCID,Powers Marissa¹,Eccles Suzanne A.¹,Clarke Paul A.¹^ORCID,Raynaud Florence I.¹^ORCID,Workman Paul¹^ORCID,Jones Keith¹^ORCID,Cheeseman Matthew D.¹^ORCID

Affiliation:

1. Centre for Cancer Drug Discovery and Division of Cancer Therapeutics at The Institute of Cancer Research, London SW7 3RP, United Kingdom

Funder

Cancer Research UK

Battle Against Cancer Investment Trust

Cancer Research Technology Pioneer Fund

Publisher

American Chemical Society (ACS)

Subject

Drug Discovery,Molecular Medicine

Link

https://pubs.acs.org/doi/pdf/10.1021/acs.jmedchem.3c00156

Reference98 articles.

1. aBanerjee, S.; Bookman, M. A.; Gore, M. Emerging Therapeutic Targets in Ovarian Cancer; Kaye, S.; Brown, R.; Gabra, H.; Gore, M., Eds. Springer, 2011; pp 1–33.

2. Global cancer statistics, 2012

3. c National Cancer Institute, B. M. SEER Cancer Stat Facts: Ovarian Cancer. Retrieved fromNational Cancer Institute. B. M. SEER Cancer Stat Facts: Ovarian Cancer. Retrieved from http://seer.cancer.gov/statfacts/html/ovary.html, accessed May 2022.

4. Molecular-targeted therapies for ovarian cancer: prospects for the future

5. Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. HSF1 renders NK cells too stressed to respond;Nature Cell Biology;2024-09-02

2. 3-Ethoxycarbonyl-1,4-benzodioxin-2-carboxylic Acid;Molbank;2024-08-19

3. Dynamic HSF2 regulation drives breast cancer progression by steering the balance between proliferation and invasion;2024-06-24

4. MYC and HSF1 Cooperate to Drive PLK1 inhibitor Sensitivity in High Grade Serous Ovarian Cancer;2024-06-13

5. Driving proteomic imbalance to combat Neurofibromatosis type I (NF1)-associated malignancy;2024-05-27